Sugammadexsodium , 97% , 343306-79-6
CAS NO.:343306-79-6
Empirical Formula: C72H104Na8O48S8
Molecular Weight: 2177.97
MDL number: MFCD09954145
Pack Size | Price | Stock | Quantity |
100mg | RMB336.80 | In Stock |
|
250mg | RMB472.00 | In Stock |
|
1g | RMB1176.00 | In Stock |
|
5g | RMB4112.00 | In Stock |
|
others | Enquire |
PRODUCT Properties
storage temp. | Inert atmosphere,Room Temperature |
solubility | DMF: 2.5 mg/ml; DMSO: 2.5 mg/ml; DMSO:PBS (pH 7.2) (1:30): 0.03 mg/ml |
form | A crystalline solid |
color | White to off-white |
InChIKey | NIOBYNJFPSIMJF-OBHNVPISNA-N |
Description and Uses
To facilitate tracheal intubation, mechanical ventilation, and surgical access, NMB agents are frequently used as non-anesthetic adjuncts in surgical procedures. Sugammadex is able to function as a pharmacologic sink of rocuronium and vecuronium, another non-depolarizing neuromuscular blocker, without the cardiovascular adverse effects experienced with reversal agents that directly interact with the cholinergic system. The γ-cyclodextrin has been designed to enhance binding of the guest by incorporating acidic side chains to promote an electrostatic interaction with the positive nitrogen of the blocker. Starting with γ-cyclodextrin, these side chains are readily installed by first halogenating with iodine or bromine to provide a handle for nucleophilic displacement with either 3-mercaptopropionic acid in the presence of sodium hydride or with 3-mercaptopropionic acid methyl ester and cesium carbonate. The latter requires hydrolysis with sodium hydroxide to generate sugammadex sodium.
Sugammadex Sodium is the first in a class of drugs called selective relaxant binding agents that offers improved termination of the paralytic effects of neuromuscular blocking agents and may have many potential peri-operative benefits.
Safety
Symbol(GHS) | GHS08 |
Signal word | Danger |
Hazard statements | H302-H334 |
Precautionary statements | P264-P270-P301+P312-P330-P501-P261-P285-P304+P341-P342+P311-P501 |